Agency Information Collection Activities; Proposed Collection; Comment Request; Medical Devices; Current Good Manufacturing Practice Quality System Regulation, 37317-37321 [2019-16260]
Download as PDF
<![CDATA[
37317
Federal Register / Vol. 84, No. 147 / Wednesday, July 31, 2019 / Notices
to identify devices that must be labeled
with a UDI and the particular version or
model associated with each device
identifier, until 3 years after it ceases to
market a version or model of a device.
Respondents who are required to
submit data to the Agency under certain
other approved information collections
(listed below) are required to include
UDI data elements for the device that is
the subject of such information
collection. Addition of the UDI data
elements is included in this burden
estimate for the conforming
amendments in the following 21 CFR
parts:
Part 803—Medical Device Reporting
(OMB control number 0910–0437),
Part 806—Medical Devices; Reports of
Corrections and Removals (OMB control
number 0910–0359),
Part 814—Premarket Approval of
Medical Devices (OMB control number
0910–0231),
Part 820—Quality System Regulation
(OMB control number 0910–0073),
Part 821—Medical Device Tracking
Requirements (OMB control number
0910–0442), and
Part 822—Postmarket Surveillance
(OMB control number 0910–0449).
FDA estimates the burden of this
collection of information as follows:
TABLE 1—ESTIMATED ANNUAL BURDEN
Number of
respondents 1
Reporting ......................................
Recordkeeping .............................
Third-Party Disclosure .................
Number of
responses per
respondent 2
6,199
5,987
5,987
Total annual
responses 3
51
51
51
316,149
305,337
305,337
Average burden
per response 4
0.023 (1 minute) ........
0.989 (59 minutes) ....
0.885 (53 minutes) ....
Total
hours 5
7,289
302,121
270,143
Total capital
costs and
operating and
maintenance
costs
$425,000
14,733,333
13,033,333
1 Maximum number of respondents for any regulatory requirement within each category. Individual regulatory requirements within the category
may involve fewer respondents.
2 Maximum number of responses for any regulatory requirement within each category. Individual regulatory requirements within the category
may involve fewer responses.
3 Maximum total annual responses for any regulatory requirement within each category. Individual regulatory requirements within the category
may involve fewer total annual responses.
4 Rounded to three decimals. Total hours reflects a more precise, non-rounded average burden per response. An approximate (non-rounded)
conversion to minutes is shown in parentheses.
5 Total hours is based on a more precise burden per response than the rounded value show in this table.
Based on a review of the information
collection since our last request for
OMB approval, we have made no
adjustments to our burden estimate.
Dated: July 24, 2019.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2019–16269 Filed 7–30–19; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2016–N–2544]
Agency Information Collection
Activities; Proposed Collection;
Comment Request; Medical Devices;
Current Good Manufacturing Practice
Quality System Regulation
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA or Agency) is
announcing an opportunity for public
comment on the proposed collection of
certain information by the Agency.
Under the Paperwork Reduction Act of
1995 (PRA), Federal Agencies are
required to publish notice in the
Federal Register concerning each
jbell on DSK3GLQ082PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
20:09 Jul 30, 2019
Jkt 247001
proposed collection of information,
including each proposed extension of an
existing collection of information, and
to allow 60 days for public comment in
response to the notice. This notice
solicits comments on recordkeeping
requirements related to the medical
devices current good manufacturing
practice (CGMP) quality system (QS)
regulation (CGMP/QS regulation).
DATES: Submit either electronic or
written comments on the collection of
information by September 30, 2019.
ADDRESSES: You may submit comments
as follows. Please note that late,
untimely filed comments will not be
considered. Electronic comments must
be submitted on or before September 30,
2019. The https://www.regulations.gov
electronic filing system will accept
comments until 11:59 p.m. Eastern Time
at the end of September 30, 2019.
Comments received by mail/hand
delivery/courier (for written/paper
submissions) will be considered timely
if they are postmarked or the delivery
service acceptance receipt is on or
before that date.
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
PO 00000
Frm 00088
Fmt 4703
Sfmt 4703
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand Delivery/Courier (for
written/paper submissions):Dockets
Management Staff (HFA–305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Dockets Management
Staff, FDA will post your comment, as
well as any attachments, except for
E:\FR\FM\31JYN1.SGM
31JYN1
jbell on DSK3GLQ082PROD with NOTICES
37318
Federal Register / Vol. 84, No. 147 / Wednesday, July 31, 2019 / Notices
information submitted, marked and
identified, as confidential, if submitted
as detailed in ‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2016–N–2544 for ‘‘Agency Information
Collection Activities; Proposed
Collection; Comment Request; Medical
Devices; Current Good Manufacturing
Practice Quality System Regulation.’’
Received comments, those filed in a
timely manner (see ADDRESSES), will be
placed in the docket and, except for
those submitted as ‘‘Confidential
Submissions,’’ publicly viewable at
https://www.regulations.gov or at the
Dockets Management Staff between 9
a.m. and 4 p.m., Monday through
Friday.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on
https://www.regulations.gov. Submit
both copies to the Dockets Management
Staff. If you do not wish your name and
contact information to be made publicly
available, you can provide this
information on the cover sheet and not
in the body of your comments and you
must identify this information as
‘‘confidential.’’ Any information marked
as ‘‘confidential’’ will not be disclosed
except in accordance with 21 CFR 10.20
and other applicable disclosure law. For
more information about FDA’s posting
of comments to public dockets, see 80
FR 56469, September 18, 2015, or access
the information at: https://www.gpo.gov/
fdsys/pkg/FR-2015-09-18/pdf/201523389.pdf.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Dockets Management
Staff, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT:
Amber Sanford, Office of Operations,
VerDate Sep<11>2014
20:09 Jul 30, 2019
Jkt 247001
Food and Drug Administration, Three
White Flint North, 10A–12M, 11601
Landsdown St., North Bethesda, MD
20852, 301–796–8867, PRAStaff@
fda.hhs.gov.
SUPPLEMENTARY INFORMATION: Under the
PRA (44 U.S.C. 3501–3520), Federal
Agencies must obtain approval from the
Office of Management and Budget
(OMB) for each collection of
information they conduct or sponsor.
‘‘Collection of information’’ is defined
in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes Agency requests
or requirements that members of the
public submit reports, keep records, or
provide information to a third party.
Section 3506(c)(2)(A) of the PRA (44
U.S.C. 3506(c)(2)(A)) requires Federal
Agencies to provide a 60-day notice in
the Federal Register concerning each
proposed collection of information,
including each proposed extension of an
existing collection of information,
before submitting the collection to OMB
for approval. To comply with this
requirement, FDA is publishing notice
of the proposed collection of
information set forth in this document.
With respect to the following
collection of information, FDA invites
comments on these topics: (1) Whether
the proposed collection of information
is necessary for the proper performance
of FDA’s functions, including whether
the information will have practical
utility; (2) the accuracy of FDA’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques,
when appropriate, and other forms of
information technology.
Medical Devices: Current Good
Manufacturing Practice Quality System
Regulation—21 CFR Part 820
OMB Control Number 0910–0073—
Extension
Under section 520(f) of the Federal
Food, Drug, and Cosmetic Act (FD&C
Act) (21 U.S.C. 360j(f)), the Secretary of
the Department of Health and Human
Services has the authority to prescribe
regulations requiring that the methods
used in, and the facilities and controls
used for, the manufacture,
preproduction design validation
(including a process to assess the
performance of a device, but not
including an evaluation of the safety
and effectiveness of a device), packing,
PO 00000
Frm 00089
Fmt 4703
Sfmt 4703
storage, and installation of a device
conform to CGMP, as described in such
regulations, to assure that the device
will be safe and effective and otherwise
in compliance with the FD&C Act.
The CGMP/QS regulation
implementing authority provided by
this statutory provision is found under
part 820 (21 CFR part 820) and sets forth
basic CGMP requirements governing the
design, manufacture, packing, labeling,
storage, installation, and servicing of all
finished medical devices intended for
human use. The authority for this
regulation is covered under sections
501, 502, 510, 513, 514, 515, 518, 519,
520, 522, 701, 704, 801, and 803 of the
FD&C Act (21 U.S.C. 351, 352, 360,
360c, 360d, 360e, 360h, 360i, 360j, 360l,
371, 374, 381, and 383). The CGMP/QS
regulation includes requirements for
purchasing and service controls,
clarifies recordkeeping requirements for
device failure and complaint
investigations, clarifies requirements for
verifying/validating production
processes and process or product
changes, and clarifies requirements for
product acceptance activities quality
data evaluations and corrections of
nonconforming product/quality
problems.
Requirements are compatible with
specifications in the international
standards ‘‘ISO 9001: Quality Systems
Model for Quality Assurance in Design/
Development, Production, Installation,
and Servicing.’’ The CGMP/QS
information collections will assist FDA
inspections of manufacturers for
compliance with QS requirements
encompassing design, production,
installation, and servicing processes.
Section 820.20(a) through (e) requires
management with executive
responsibility to establish, maintain,
and/or review the following topics: (1)
The quality policy, (2) the
organizational structure, (3) the quality
plan, and (4) the quality system
procedures of the organization. Section
820.22 requires the conduct and
documentation of QS audits and
reaudits. Section 820.25(b) requires the
establishment of procedures to identify
training needs and documentation of
such training.
Section 820.30(a)(1) and (b) through
(j) requires, in respective order, the
establishment, maintenance, and/or
documentation of the following topics:
(1) Procedures to control design of class
III and class II devices and certain class
I devices as listed therein; (2) plans for
design and development activities and
updates; (3) procedures identifying,
documenting, and approving design
input requirements; (4) procedures
defining design output, including
E:\FR\FM\31JYN1.SGM
31JYN1
jbell on DSK3GLQ082PROD with NOTICES
Federal Register / Vol. 84, No. 147 / Wednesday, July 31, 2019 / Notices
acceptance criteria, and documentation
of approved records; (5) procedures for
formal review of design results and
documentation of results in the design
history file (DHF); (6) procedures for
verifying device design and
documentation of results and approvals
in the DHF; (7) procedures for validating
device design, including documentation
of results in the DHF; (8) procedures for
translating device design into
production specifications; (9)
procedures for documenting, verifying,
and validating approved design changes
before implementation of changes; and
(10) the records and references
constituting the DHF for each type of
device.
Section 820.40 requires manufacturers
to establish and maintain procedures
controlling approval and distribution of
required documents and document
changes. Section 820.40(a) and (b)
requires the establishment and
maintenance of procedures for the
review, approval, issuance, and
documentation of required records
(documents) and changes to those
records.
Section 820.50(a) and (b) requires the
establishment and maintenance of
procedures and requirements to ensure
service and product quality, records of
acceptable suppliers, and purchasing
data describing specified requirements
for products and services.
Sections 820.60 and 820.65 require,
respectively, the establishment and
maintenance of procedures for
identifying all products from receipt to
distribution and for using control
numbers to track surgical implants and
life-sustaining or supporting devices
and their components.
Section 820.70(a) through (e), (g)(1)
through (3), (h), and (i) requires the
establishment, maintenance, and/or
documentation of the following topics:
(1) Process control procedures; (2)
procedures for verifying or validating
changes to specification, method,
process, or procedure; (3) procedures to
control environmental conditions and
inspection result records; (4)
requirements for personnel hygiene; (5)
procedures for preventing
contamination of equipment and
products; (6) equipment adjustment,
cleaning, and maintenance schedules;
(7) equipment inspection records; (8)
equipment tolerance postings,
procedures for utilizing manufacturing
materials expected to have an adverse
effect on product quality; and (9)
validation protocols and validation
records for computer software and
software changes.
Sections 820.72(a), (b)(1) and (2), and
820.75(a) through (c) require,
VerDate Sep<11>2014
20:09 Jul 30, 2019
Jkt 247001
respectively, the establishment,
maintenance, and/or documentation of
the following topics: (1) Equipment
calibration and inspection procedures;
(2) national, international, or in-house
calibration standards; (3) records that
identify calibrated equipment and next
calibration dates; (4) validation
procedures and validation results for
processes not verifiable by inspections
and tests; (5) procedures for keeping
validated processes within specified
limits; (6) records for monitoring and
controlling validated processes; and (7)
records of the results of revalidation
where necessitated by process changes
or deviations.
Sections 820.80(a) through (e) and
820.86, respectively, require the
establishment, maintenance, and/or
documentation of the following topics:
(1) Procedures for incoming acceptance
by inspection, test, or other verification;
(2) procedures for ensuring that inprocess products meet specified
requirements and the control of product
until inspection and tests are
completed; (3) procedures for, and
records that show, incoming acceptance
or rejection is conducted by inspections,
tests, or other verifications; (4)
procedures for, and records that show,
finished devices meet acceptance
criteria and are not distributed until
device master record (DMR) activities
are completed; (5) records in the device
history record (DHR) showing
acceptance dates, results, and
equipment used; and (6) the acceptance/
rejection identification of products from
receipt to installation and servicing.
Sections 820.90(a), (b)(1) and (2), and
820.100 require, respectively, the
establishment, maintenance and/or
documentation of the following topics:
(1) Procedures for identifying,
recording, evaluating, and disposing of
nonconforming product; (2) procedures
for reviewing and recording concessions
made for, and disposition of,
nonconforming product; (3) procedures
for reworking products, evaluating
possible adverse rework effect and
recording results in the DHR; (4)
procedures and requirements for
corrective and preventive actions,
including analysis, investigation,
identification and review of data,
records, causes, and results; and (5)
records for all corrective and preventive
action activities.
Section 820.100(a)(1) through (7)
states that procedures and requirements
shall be established and maintained for
corrective/preventive actions, including
the following: (1) Analysis of data from
process, work, quality, servicing
records, investigation of
nonconformance causes; (2)
PO 00000
Frm 00090
Fmt 4703
Sfmt 4703
37319
identification of corrections and their
effectiveness; (3) recording of changes
made; and (4) appropriate distribution
and managerial review of corrective and
preventive action information. Section
820.120 states that manufacturers shall
establish/maintain procedures to control
labeling storage/application,
examination/release for storage and use,
and to document those procedures.
Sections 820.120(b) and (d), 820.130,
820.140, 820.150(a) and (b), 820.160(a)
and (b), and 820.170(a) and (b),
respectively, require the establishment,
maintenance, and/or documentation of
the following topics: (1) Procedures for
controlling and recording the storage,
examination, release, and use of
labeling; (2) the filing of labels/labeling
used in the DHR; (3) procedures for
controlling product storage areas and
receipt/dispatch authorizations; (4)
procedures controlling the release of
products for distribution; (5)
distribution records that identify
consignee, product, date, and control
numbers; and (6) instructions,
inspection and test procedures that are
made available, and the recording of
results for devices requiring installation.
Sections 820.180(b) and (c),
820.181(a) through (e), 820.184(a)
through (f), and 820.186 require,
respectively, the maintenance of records
that are: (1) Retained at prescribed
site(s), made readily available and
accessible to FDA, and retained for the
device’s life expectancy or for 2 years;
(2) contained or referenced in a DMR
consisting of device, process, quality
assurance, packaging and labeling, and
installation, maintenance, and servicing
specifications and procedures; (3)
contained in a DHR and demonstrate the
manufacture of each unit, lot, or batch
of product in conformance with DMR
and regulatory requirements include
manufacturing and distribution dates,
quantities, acceptance documents,
labels and labeling, and control
numbers; and (4) contained in a quality
system record, consisting of references,
documents, procedures, and activities
not specific to particular devices.
Sections 820.198(a) through (g) and
820.200(a) through (d), respectively,
require the establishment, maintenance,
and/or documentation of the following
topics: (1) Complaint files and
procedures for receiving, reviewing, and
evaluating complaints; (2) complaint
investigation records identifying the
device, complainant, and relationship of
the device to the incident; (3) complaint
records that are reasonably accessible to
the manufacturing site or at prescribed
sites; (4) procedures for performing and
verifying that device servicing
requirements are met and that service
E:\FR\FM\31JYN1.SGM
31JYN1
37320
Federal Register / Vol. 84, No. 147 / Wednesday, July 31, 2019 / Notices
reports involving complaints are
processed as complaints; and (5) service
reports that record the device, service
activity, and test and inspection data.
Section 820.250 requires the
establishment and maintenance of
procedures to identify valid statistical
techniques necessary to verify process
and product acceptability; and sampling
plans, when used, which are written
and based on valid statistical rationale;
and procedures for ensuring adequate
sampling methods.
The CGMP/QS regulation added
design and purchasing controls,
modified previous critical device
requirements, revised previous
validation and other requirements, and
harmonized device CGMP requirements
with QS specifications in the
international standard ‘‘ISO 9001:
Quality Systems Model for Quality
Assurance in Design/Development,
Production, Installation, and Servicing.’’
The rule does not apply to
manufacturers of components or parts of
finished devices, or to manufacturers of
human blood and blood components
subject to 21 CFR part 606. With respect
to devices classified in class I, design
control requirements apply only to class
I devices listed in § 820.30(a)(2) of the
regulation. The rule imposes burden
upon: (1) Finished device manufacturer
firms, which are subject to all
recordkeeping requirements; (2)
finished device contract manufacturers,
specification developers; and (3) repacker, re-labelers, and contract
sterilizer firms, which are subject only
to requirements applicable to their
activities. In addition, remanufacturers
of hospital single-use devices are now
considered to have the same
requirements as manufacturers in regard
to the regulation.
The establishment, maintenance, and/
or documentation of procedures,
records, and data required by the
regulation assists FDA in determining
whether firms are in compliance with
CGMP requirements, which are
intended to ensure that devices meet
their design, production, labeling,
installation, and servicing specifications
and, thus are safe, effective, and suitable
for their intended purpose. In particular,
compliance with CGMP design control
requirements should decrease the
number of design-related device failures
that have resulted in deaths and serious
injuries.
The CGMP/QS regulation applies to
approximately 27,074 respondents. This
estimate is based on a query of the
Agency’s registration and listing
database. Respondents to this
information collection have no reporting
activities, but must make required
records available for review or copying
during FDA inspection. Except for
manufacturers, not every type of firm is
subject to every CGMP/QS requirement.
For example, all are subject to Quality
Policy (§ 820.20(a)), Document Control
(§ 820.40), and other requirements,
whereas only manufacturers and
specification developers are subject to
subpart C, Design Controls. The PRA
burden placed on the 27,074
establishments is an average burden.
FDA estimates the burden of this
collection of information as follows:
TABLE 1—ESTIMATED ANNUAL RECORDKEEPING BURDEN 1
Number of
recordkeepers
jbell on DSK3GLQ082PROD with NOTICES
Activity/21 CFR section
Quality policy—820.20(a) .....................................................
Organization—820.20(b) ......................................................
Management review—820.20(c) ..........................................
Quality planning—820.20(d) ................................................
Quality system procedures—820.20(e) ...............................
Quality audit—820.22 ..........................................................
Training—820.25(b) .............................................................
Design procedures—820.30(a)(1) .......................................
Design and development planning—820.30(b) ...................
Design input—820.30(c) ......................................................
Design output—820.30(d) ....................................................
Design review—820.30(e) ...................................................
Design verification—820.30(f) ..............................................
Design validation—820.30(g) ...............................................
Design transfer—820.30(h) ..................................................
Design changes—820.30(i) .................................................
Design history file—820.30(j) ...............................................
Document controls—820.40 ................................................
Documentation approval and distribution and document
changes—820.40(a) and (b) ............................................
Purchasing controls—820.50(a) ..........................................
Purchasing data—820.50(b) ................................................
Identification—820.60 ..........................................................
Traceability—820.65 ............................................................
Production and process controls—820.70(a) ......................
Production and process changes and environmental control—820.70(b) and (c) .....................................................
Personnel—820.70(d) ..........................................................
Contamination control—820.70(e) .......................................
Equipment maintenance schedule, inspection, and adjustment—820.70(g)(1)–(3) ....................................................
Manufacturing material—820.70(h) .....................................
Automated processes—820.70(i) ........................................
Control of inspection, measuring, and test equipment—
820.72(a) ..........................................................................
Calibration procedures, standards, and records—
820.72(b)(1)–(2) ...............................................................
Process validation—820.75(a) .............................................
VerDate Sep<11>2014
20:09 Jul 30, 2019
Jkt 247001
PO 00000
Frm 00091
Number of
records per
recordkeeper
Total annual
records
Average
burden per
recordkeeping
Total hours
27,074
27,074
27,074
27,074
27,074
27,074
27,074
27,074
27,074
27,074
27,074
27,074
27,074
27,074
27,074
27,074
27,074
27,074
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
27,074
27,074
27,074
27,074
27,074
27,074
27,074
27,074
27,074
27,074
27,074
27,074
27,074
27,074
27,074
27,074
27,074
27,074
7
4
6
10
10
33
13
2
6
2
2
23
37
37
3
17
3
9
189,518
108,296
162,444
270,740
270,740
893,442
351,962
54,148
162,444
54,148
54,148
622,702
1,001,738
1,001,738
81,222
460,258
81,222
243,666
27,074
27,074
27,074
27,074
27,074
27,074
1
1
1
1
1
1
27,074
27,074
27,074
27,074
27,074
27,074
2
22
6
1
1
2
54,148
595,628
162,444
27,074
27,074
54,148
27,074
27,074
27,074
1
1
1
27,074
27,074
27,074
2
3
2
54,148
81,222
54,148
27,074
27,074
27,074
1
1
1
27,074
27,074
27,074
1
2
8
27,074
54,148
216,592
27,074
1
27,074
5
135,370
27,074
27,074
1
1
27,074
27,074
1
3
27,074
81,222
Fmt 4703
Sfmt 4703
E:\FR\FM\31JYN1.SGM
31JYN1
37321
Federal Register / Vol. 84, No. 147 / Wednesday, July 31, 2019 / Notices
TABLE 1—ESTIMATED ANNUAL RECORDKEEPING BURDEN 1—Continued
Number of
recordkeepers
Activity/21 CFR section
Validated process parameters, monitoring, control methods, and data—820.75(b) ................................................
Revalidation—820.75(c) .......................................................
Acceptance activities—820.80(a)–(e) ..................................
Acceptance status—820.86 .................................................
Control of nonconforming product—820.90(a) ....................
Nonconforming product review/disposition procedures and
rework procedures—820.90(b)(1)–(2) ..............................
Procedures
for
corrective/preventive
actions—
820.100(a)(1)–(7) .............................................................
Corrective/preventive activities—820.100(b) .......................
Labeling procedures—820.120(b) .......................................
Labeling documentation—820.120(d) ..................................
Device packaging—820.130 ................................................
Handling—820.140 ..............................................................
Storage—820.150(a) and (b) ...............................................
Distribution procedures and records—820.160(a) and (b) ..
Installation—820.170 ...........................................................
Record retention period—820.180(b) and (c) ......................
Device master record—820.181 ..........................................
Device history record—820.184 ..........................................
Quality system record—820.186 .........................................
Complaint files—820.198(a)–(g) ..........................................
Servicing procedures and reports—820.200(a) and (d) ......
Statistical techniques procedures and sampling plans—
820.250 .............................................................................
Total ..............................................................................
1 There
Dated: July 24, 2019.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2019–16260 Filed 7–30–19; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2013–N–0579]
Agency Information Collection
Activities; Proposed Collection;
Comment Request; Biological
Products: Reporting of Biological
Product Deviations and Human Cells,
Tissues, and Cellular and TissueBased Deviations in Manufacturing
jbell on DSK3GLQ082PROD with NOTICES
Food and Drug Administration,
HHS.
ACTION:
Total annual
records
Average
burden per
recordkeeping
Total hours
27,074
27,074
27,074
27,074
27,074
1
1
1
1
1
27,074
27,074
27,074
27,074
27,074
1
1
5
1
5
27,074
27,074
135,370
27,074
135,370
27,074
1
27,074
5
135,370
27,074
27,074
27,074
27,074
27,074
27,074
27,074
27,074
27,074
27,074
27,074
27,074
27,074
27,074
27,074
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
27,074
27,074
27,074
27,074
27,074
27,074
27,074
27,074
27,074
27,074
27,074
27,074
27,074
27,074
27,074
12
1
1
1
1
6
6
1
2
2
1
1
1
5
3
324,888
27,074
27,074
27,074
27,074
162,444
162,444
27,074
54,148
54,148
27,074
27,074
27,074
135,370
81,222
27,074
1
27,074
1
27,074
........................
........................
........................
........................
9,421,752
are no capital costs or operating and maintenance costs associated with this collection of information.
Our estimated burden for the
information collection reflects an
overall increase of 812,928 hours. We
attribute this adjustment to an increase
in the number of respondents.
AGENCY:
Number of
records per
recordkeeper
Notice.
The Food and Drug
Administration (FDA or Agency) is
announcing an opportunity for public
comment on the proposed collection of
SUMMARY:
VerDate Sep<11>2014
20:09 Jul 30, 2019
Jkt 247001
certain information by the Agency.
Under the Paperwork Reduction Act of
1995 (PRA), Federal Agencies are
required to publish notice in the
Federal Register concerning each
proposed collection of information,
including each proposed extension of an
existing collection of information, and
to allow 60 days for public comment in
response to the notice. This notice
solicits comments on the information
collection requirements relating to the
reporting of biological product
deviations and human cells, tissues, and
cellular and tissue-based product (HCT/
P) deviations in manufacturing, and
Forms FDA 3486 and 3486A.July 31,
2019
DATES: Submit electronic or written
comments on the collection of
information by September 30, 2019.
ADDRESSES: You may submit comments
as follows. Please note that late,
untimely filed comments will not be
considered. Electronic comments must
be submitted on or before September 30,
2019. The https://www.regulations.gov
electronic filing system will accept
comments until 11:59 p.m. Eastern Time
at the end of September 30, 2019.
Comments received by mail/hand
delivery/courier (for written/paper
submissions) will be considered timely
if they are postmarked or the delivery
PO 00000
Frm 00092
Fmt 4703
Sfmt 4703
service acceptance receipt is on or
before that date.
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal: https://
www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
E:\FR\FM\31JYN1.SGM
31JYN1
]]>Agencies
[Federal Register Volume 84, Number 147 (Wednesday, July 31, 2019)]
[Notices]
[Pages 37317-37321]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-16260]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2016-N-2544]
Agency Information Collection Activities; Proposed Collection;
Comment Request; Medical Devices; Current Good Manufacturing Practice
Quality System Regulation
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing
an opportunity for public comment on the proposed collection of certain
information by the Agency. Under the Paperwork Reduction Act of 1995
(PRA), Federal Agencies are required to publish notice in the Federal
Register concerning each proposed collection of information, including
each proposed extension of an existing collection of information, and
to allow 60 days for public comment in response to the notice. This
notice solicits comments on recordkeeping requirements related to the
medical devices current good manufacturing practice (CGMP) quality
system (QS) regulation (CGMP/QS regulation).
DATES: Submit either electronic or written comments on the collection
of information by September 30, 2019.
ADDRESSES: You may submit comments as follows. Please note that late,
untimely filed comments will not be considered. Electronic comments
must be submitted on or before September 30, 2019. The https://www.regulations.gov electronic filing system will accept comments until
11:59 p.m. Eastern Time at the end of September 30, 2019. Comments
received by mail/hand delivery/courier (for written/paper submissions)
will be considered timely if they are postmarked or the delivery
service acceptance receipt is on or before that date.
Electronic Submissions
Submit electronic comments in the following way:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on https://www.regulations.gov.
If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').
Written/Paper Submissions
Submit written/paper submissions as follows:
Mail/Hand Delivery/Courier (for written/paper
submissions):Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
For written/paper comments submitted to the Dockets
Management Staff, FDA will post your comment, as well as any
attachments, except for
[[Page 37318]]
information submitted, marked and identified, as confidential, if
submitted as detailed in ``Instructions.''
Instructions: All submissions received must include the Docket No.
FDA-2016-N-2544 for ``Agency Information Collection Activities;
Proposed Collection; Comment Request; Medical Devices; Current Good
Manufacturing Practice Quality System Regulation.'' Received comments,
those filed in a timely manner (see ADDRESSES), will be placed in the
docket and, except for those submitted as ``Confidential Submissions,''
publicly viewable at https://www.regulations.gov or at the Dockets
Management Staff between 9 a.m. and 4 p.m., Monday through Friday.
Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information redacted/blacked out, will be
available for public viewing and posted on https://www.regulations.gov.
Submit both copies to the Dockets Management Staff. If you do not wish
your name and contact information to be made publicly available, you
can provide this information on the cover sheet and not in the body of
your comments and you must identify this information as
``confidential.'' Any information marked as ``confidential'' will not
be disclosed except in accordance with 21 CFR 10.20 and other
applicable disclosure law. For more information about FDA's posting of
comments to public dockets, see 80 FR 56469, September 18, 2015, or
access the information at: https://www.gpo.gov/fdsys/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT: Amber Sanford, Office of Operations,
Food and Drug Administration, Three White Flint North, 10A-12M, 11601
Landsdown St., North Bethesda, MD 20852, 301-796-8867,
[email protected].
SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3520), Federal
Agencies must obtain approval from the Office of Management and Budget
(OMB) for each collection of information they conduct or sponsor.
``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes Agency requests or requirements that members of
the public submit reports, keep records, or provide information to a
third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A))
requires Federal Agencies to provide a 60-day notice in the Federal
Register concerning each proposed collection of information, including
each proposed extension of an existing collection of information,
before submitting the collection to OMB for approval. To comply with
this requirement, FDA is publishing notice of the proposed collection
of information set forth in this document.
With respect to the following collection of information, FDA
invites comments on these topics: (1) Whether the proposed collection
of information is necessary for the proper performance of FDA's
functions, including whether the information will have practical
utility; (2) the accuracy of FDA's estimate of the burden of the
proposed collection of information, including the validity of the
methodology and assumptions used; (3) ways to enhance the quality,
utility, and clarity of the information to be collected; and (4) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques, when
appropriate, and other forms of information technology.
Medical Devices: Current Good Manufacturing Practice Quality System
Regulation--21 CFR Part 820
OMB Control Number 0910-0073--Extension
Under section 520(f) of the Federal Food, Drug, and Cosmetic Act
(FD&C Act) (21 U.S.C. 360j(f)), the Secretary of the Department of
Health and Human Services has the authority to prescribe regulations
requiring that the methods used in, and the facilities and controls
used for, the manufacture, preproduction design validation (including a
process to assess the performance of a device, but not including an
evaluation of the safety and effectiveness of a device), packing,
storage, and installation of a device conform to CGMP, as described in
such regulations, to assure that the device will be safe and effective
and otherwise in compliance with the FD&C Act.
The CGMP/QS regulation implementing authority provided by this
statutory provision is found under part 820 (21 CFR part 820) and sets
forth basic CGMP requirements governing the design, manufacture,
packing, labeling, storage, installation, and servicing of all finished
medical devices intended for human use. The authority for this
regulation is covered under sections 501, 502, 510, 513, 514, 515, 518,
519, 520, 522, 701, 704, 801, and 803 of the FD&C Act (21 U.S.C. 351,
352, 360, 360c, 360d, 360e, 360h, 360i, 360j, 360l, 371, 374, 381, and
383). The CGMP/QS regulation includes requirements for purchasing and
service controls, clarifies recordkeeping requirements for device
failure and complaint investigations, clarifies requirements for
verifying/validating production processes and process or product
changes, and clarifies requirements for product acceptance activities
quality data evaluations and corrections of nonconforming product/
quality problems.
Requirements are compatible with specifications in the
international standards ``ISO 9001: Quality Systems Model for Quality
Assurance in Design/Development, Production, Installation, and
Servicing.'' The CGMP/QS information collections will assist FDA
inspections of manufacturers for compliance with QS requirements
encompassing design, production, installation, and servicing processes.
Section 820.20(a) through (e) requires management with executive
responsibility to establish, maintain, and/or review the following
topics: (1) The quality policy, (2) the organizational structure, (3)
the quality plan, and (4) the quality system procedures of the
organization. Section 820.22 requires the conduct and documentation of
QS audits and reaudits. Section 820.25(b) requires the establishment of
procedures to identify training needs and documentation of such
training.
Section 820.30(a)(1) and (b) through (j) requires, in respective
order, the establishment, maintenance, and/or documentation of the
following topics: (1) Procedures to control design of class III and
class II devices and certain class I devices as listed therein; (2)
plans for design and development activities and updates; (3) procedures
identifying, documenting, and approving design input requirements; (4)
procedures defining design output, including
[[Page 37319]]
acceptance criteria, and documentation of approved records; (5)
procedures for formal review of design results and documentation of
results in the design history file (DHF); (6) procedures for verifying
device design and documentation of results and approvals in the DHF;
(7) procedures for validating device design, including documentation of
results in the DHF; (8) procedures for translating device design into
production specifications; (9) procedures for documenting, verifying,
and validating approved design changes before implementation of
changes; and (10) the records and references constituting the DHF for
each type of device.
Section 820.40 requires manufacturers to establish and maintain
procedures controlling approval and distribution of required documents
and document changes. Section 820.40(a) and (b) requires the
establishment and maintenance of procedures for the review, approval,
issuance, and documentation of required records (documents) and changes
to those records.
Section 820.50(a) and (b) requires the establishment and
maintenance of procedures and requirements to ensure service and
product quality, records of acceptable suppliers, and purchasing data
describing specified requirements for products and services.
Sections 820.60 and 820.65 require, respectively, the establishment
and maintenance of procedures for identifying all products from receipt
to distribution and for using control numbers to track surgical
implants and life-sustaining or supporting devices and their
components.
Section 820.70(a) through (e), (g)(1) through (3), (h), and (i)
requires the establishment, maintenance, and/or documentation of the
following topics: (1) Process control procedures; (2) procedures for
verifying or validating changes to specification, method, process, or
procedure; (3) procedures to control environmental conditions and
inspection result records; (4) requirements for personnel hygiene; (5)
procedures for preventing contamination of equipment and products; (6)
equipment adjustment, cleaning, and maintenance schedules; (7)
equipment inspection records; (8) equipment tolerance postings,
procedures for utilizing manufacturing materials expected to have an
adverse effect on product quality; and (9) validation protocols and
validation records for computer software and software changes.
Sections 820.72(a), (b)(1) and (2), and 820.75(a) through (c)
require, respectively, the establishment, maintenance, and/or
documentation of the following topics: (1) Equipment calibration and
inspection procedures; (2) national, international, or in-house
calibration standards; (3) records that identify calibrated equipment
and next calibration dates; (4) validation procedures and validation
results for processes not verifiable by inspections and tests; (5)
procedures for keeping validated processes within specified limits; (6)
records for monitoring and controlling validated processes; and (7)
records of the results of revalidation where necessitated by process
changes or deviations.
Sections 820.80(a) through (e) and 820.86, respectively, require
the establishment, maintenance, and/or documentation of the following
topics: (1) Procedures for incoming acceptance by inspection, test, or
other verification; (2) procedures for ensuring that in-process
products meet specified requirements and the control of product until
inspection and tests are completed; (3) procedures for, and records
that show, incoming acceptance or rejection is conducted by
inspections, tests, or other verifications; (4) procedures for, and
records that show, finished devices meet acceptance criteria and are
not distributed until device master record (DMR) activities are
completed; (5) records in the device history record (DHR) showing
acceptance dates, results, and equipment used; and (6) the acceptance/
rejection identification of products from receipt to installation and
servicing.
Sections 820.90(a), (b)(1) and (2), and 820.100 require,
respectively, the establishment, maintenance and/or documentation of
the following topics: (1) Procedures for identifying, recording,
evaluating, and disposing of nonconforming product; (2) procedures for
reviewing and recording concessions made for, and disposition of,
nonconforming product; (3) procedures for reworking products,
evaluating possible adverse rework effect and recording results in the
DHR; (4) procedures and requirements for corrective and preventive
actions, including analysis, investigation, identification and review
of data, records, causes, and results; and (5) records for all
corrective and preventive action activities.
Section 820.100(a)(1) through (7) states that procedures and
requirements shall be established and maintained for corrective/
preventive actions, including the following: (1) Analysis of data from
process, work, quality, servicing records, investigation of
nonconformance causes; (2) identification of corrections and their
effectiveness; (3) recording of changes made; and (4) appropriate
distribution and managerial review of corrective and preventive action
information. Section 820.120 states that manufacturers shall establish/
maintain procedures to control labeling storage/application,
examination/release for storage and use, and to document those
procedures.
Sections 820.120(b) and (d), 820.130, 820.140, 820.150(a) and (b),
820.160(a) and (b), and 820.170(a) and (b), respectively, require the
establishment, maintenance, and/or documentation of the following
topics: (1) Procedures for controlling and recording the storage,
examination, release, and use of labeling; (2) the filing of labels/
labeling used in the DHR; (3) procedures for controlling product
storage areas and receipt/dispatch authorizations; (4) procedures
controlling the release of products for distribution; (5) distribution
records that identify consignee, product, date, and control numbers;
and (6) instructions, inspection and test procedures that are made
available, and the recording of results for devices requiring
installation.
Sections 820.180(b) and (c), 820.181(a) through (e), 820.184(a)
through (f), and 820.186 require, respectively, the maintenance of
records that are: (1) Retained at prescribed site(s), made readily
available and accessible to FDA, and retained for the device's life
expectancy or for 2 years; (2) contained or referenced in a DMR
consisting of device, process, quality assurance, packaging and
labeling, and installation, maintenance, and servicing specifications
and procedures; (3) contained in a DHR and demonstrate the manufacture
of each unit, lot, or batch of product in conformance with DMR and
regulatory requirements include manufacturing and distribution dates,
quantities, acceptance documents, labels and labeling, and control
numbers; and (4) contained in a quality system record, consisting of
references, documents, procedures, and activities not specific to
particular devices.
Sections 820.198(a) through (g) and 820.200(a) through (d),
respectively, require the establishment, maintenance, and/or
documentation of the following topics: (1) Complaint files and
procedures for receiving, reviewing, and evaluating complaints; (2)
complaint investigation records identifying the device, complainant,
and relationship of the device to the incident; (3) complaint records
that are reasonably accessible to the manufacturing site or at
prescribed sites; (4) procedures for performing and verifying that
device servicing requirements are met and that service
[[Page 37320]]
reports involving complaints are processed as complaints; and (5)
service reports that record the device, service activity, and test and
inspection data.
Section 820.250 requires the establishment and maintenance of
procedures to identify valid statistical techniques necessary to verify
process and product acceptability; and sampling plans, when used, which
are written and based on valid statistical rationale; and procedures
for ensuring adequate sampling methods.
The CGMP/QS regulation added design and purchasing controls,
modified previous critical device requirements, revised previous
validation and other requirements, and harmonized device CGMP
requirements with QS specifications in the international standard ``ISO
9001: Quality Systems Model for Quality Assurance in Design/
Development, Production, Installation, and Servicing.'' The rule does
not apply to manufacturers of components or parts of finished devices,
or to manufacturers of human blood and blood components subject to 21
CFR part 606. With respect to devices classified in class I, design
control requirements apply only to class I devices listed in Sec.
820.30(a)(2) of the regulation. The rule imposes burden upon: (1)
Finished device manufacturer firms, which are subject to all
recordkeeping requirements; (2) finished device contract manufacturers,
specification developers; and (3) re-packer, re-labelers, and contract
sterilizer firms, which are subject only to requirements applicable to
their activities. In addition, remanufacturers of hospital single-use
devices are now considered to have the same requirements as
manufacturers in regard to the regulation.
The establishment, maintenance, and/or documentation of procedures,
records, and data required by the regulation assists FDA in determining
whether firms are in compliance with CGMP requirements, which are
intended to ensure that devices meet their design, production,
labeling, installation, and servicing specifications and, thus are
safe, effective, and suitable for their intended purpose. In
particular, compliance with CGMP design control requirements should
decrease the number of design-related device failures that have
resulted in deaths and serious injuries.
The CGMP/QS regulation applies to approximately 27,074 respondents.
This estimate is based on a query of the Agency's registration and
listing database. Respondents to this information collection have no
reporting activities, but must make required records available for
review or copying during FDA inspection. Except for manufacturers, not
every type of firm is subject to every CGMP/QS requirement. For
example, all are subject to Quality Policy (Sec. 820.20(a)), Document
Control (Sec. 820.40), and other requirements, whereas only
manufacturers and specification developers are subject to subpart C,
Design Controls. The PRA burden placed on the 27,074 establishments is
an average burden.
FDA estimates the burden of this collection of information as
follows:
Table 1--Estimated Annual Recordkeeping Burden \1\
----------------------------------------------------------------------------------------------------------------
Number of Average
Activity/21 CFR section Number of records per Total annual burden per Total hours
recordkeepers recordkeeper records recordkeeping
----------------------------------------------------------------------------------------------------------------
Quality policy--820.20(a)....... 27,074 1 27,074 7 189,518
Organization--820.20(b)......... 27,074 1 27,074 4 108,296
Management review--820.20(c).... 27,074 1 27,074 6 162,444
Quality planning--820.20(d)..... 27,074 1 27,074 10 270,740
Quality system procedures-- 27,074 1 27,074 10 270,740
820.20(e)......................
Quality audit--820.22........... 27,074 1 27,074 33 893,442
Training--820.25(b)............. 27,074 1 27,074 13 351,962
Design procedures--820.30(a)(1). 27,074 1 27,074 2 54,148
Design and development planning-- 27,074 1 27,074 6 162,444
820.30(b)......................
Design input--820.30(c)......... 27,074 1 27,074 2 54,148
Design output--820.30(d)........ 27,074 1 27,074 2 54,148
Design review--820.30(e)........ 27,074 1 27,074 23 622,702
Design verification--820.30(f).. 27,074 1 27,074 37 1,001,738
Design validation--820.30(g).... 27,074 1 27,074 37 1,001,738
Design transfer--820.30(h)...... 27,074 1 27,074 3 81,222
Design changes--820.30(i)....... 27,074 1 27,074 17 460,258
Design history file--820.30(j).. 27,074 1 27,074 3 81,222
Document controls--820.40....... 27,074 1 27,074 9 243,666
Documentation approval and 27,074 1 27,074 2 54,148
distribution and document
changes--820.40(a) and (b).....
Purchasing controls--820.50(a).. 27,074 1 27,074 22 595,628
Purchasing data--820.50(b)...... 27,074 1 27,074 6 162,444
Identification--820.60.......... 27,074 1 27,074 1 27,074
Traceability--820.65............ 27,074 1 27,074 1 27,074
Production and process controls-- 27,074 1 27,074 2 54,148
820.70(a)......................
Production and process changes 27,074 1 27,074 2 54,148
and environmental control--
820.70(b) and (c)..............
Personnel--820.70(d)............ 27,074 1 27,074 3 81,222
Contamination control--820.70(e) 27,074 1 27,074 2 54,148
Equipment maintenance schedule, 27,074 1 27,074 1 27,074
inspection, and adjustment--
820.70(g)(1)-(3)...............
Manufacturing material-- 27,074 1 27,074 2 54,148
820.70(h)......................
Automated processes--820.70(i).. 27,074 1 27,074 8 216,592
Control of inspection, 27,074 1 27,074 5 135,370
measuring, and test equipment--
820.72(a)......................
Calibration procedures, 27,074 1 27,074 1 27,074
standards, and records--
820.72(b)(1)-(2)...............
Process validation--820.75(a)... 27,074 1 27,074 3 81,222
[[Page 37321]]
Validated process parameters, 27,074 1 27,074 1 27,074
monitoring, control methods,
and data--820.75(b)............
Revalidation--820.75(c)......... 27,074 1 27,074 1 27,074
Acceptance activities--820.80(a)- 27,074 1 27,074 5 135,370
(e)............................
Acceptance status--820.86....... 27,074 1 27,074 1 27,074
Control of nonconforming 27,074 1 27,074 5 135,370
product--820.90(a).............
Nonconforming product review/ 27,074 1 27,074 5 135,370
disposition procedures and
rework procedures--820.90(b)(1)-
(2)............................
Procedures for corrective/ 27,074 1 27,074 12 324,888
preventive actions--
820.100(a)(1)-(7)..............
Corrective/preventive 27,074 1 27,074 1 27,074
activities--820.100(b).........
Labeling procedures--820.120(b). 27,074 1 27,074 1 27,074
Labeling documentation-- 27,074 1 27,074 1 27,074
820.120(d).....................
Device packaging--820.130....... 27,074 1 27,074 1 27,074
Handling--820.140............... 27,074 1 27,074 6 162,444
Storage--820.150(a) and (b)..... 27,074 1 27,074 6 162,444
Distribution procedures and 27,074 1 27,074 1 27,074
records--820.160(a) and (b)....
Installation--820.170........... 27,074 1 27,074 2 54,148
Record retention period-- 27,074 1 27,074 2 54,148
820.180(b) and (c).............
Device master record--820.181... 27,074 1 27,074 1 27,074
Device history record--820.184.. 27,074 1 27,074 1 27,074
Quality system record--820.186.. 27,074 1 27,074 1 27,074
Complaint files--820.198(a)-(g). 27,074 1 27,074 5 135,370
Servicing procedures and 27,074 1 27,074 3 81,222
reports--820.200(a) and (d)....
Statistical techniques 27,074 1 27,074 1 27,074
procedures and sampling plans--
820.250........................
-------------------------------------------------------------------------------
Total....................... .............. .............. .............. .............. 9,421,752
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
information.
Our estimated burden for the information collection reflects an
overall increase of 812,928 hours. We attribute this adjustment to an
increase in the number of respondents.
Dated: July 24, 2019.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2019-16260 Filed 7-30-19; 8:45 am]
BILLING CODE 4164-01-P
